AstraZeneca’s Cancer Drug Trial Disappoints, Sending Shares Lower

The treatment had been expected to be a crucial driver of growth for the company as it faces more competition from generic pharmaceuticals.

from NYT > Health http://ift.tt/2v0P78C
via health&fitness